Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited (TEVA)

Schulhoff & Co. Inc. now owns 11,601 shares of the company's stock valued at $372,000 after buying an additional 1,004 shares during the period. The Camber Capital Management Llc holds 4.72M shares with $171.26M value, up from 2.00 million last quarter. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a "buy" rating in a research note on Thursday, April 6th. SELL rating has been given by 0 analyst (s) and 2 analyst (s) given BUY rating to the stock. NEXT Financial Group Inc now owns 10,574 shares of the company's stock valued at $351,000 after buying an additional 6,350 shares during the last quarter. Bank Hapoalim BM raised its position in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Whereas, in last 21 trading days (one month) was surged -27.39% and slashed in last 63 trading days (quarter) of -23.06%.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) belongs to Healthcare sector, to cut down amount of noise on price chart, shares of firm has 20 days moving average price of -25.98% from last close price of 23.75 and act as support or resistance of price limit. A company that manages their assets well will have a high return, while if manages their assets poorly will have a low return. The company has a 50 day moving average price of $32.05 and a 200-day moving average price of $32.28.

Teva also cut its 2017 sales guidance to $22.8 billion to $23.2 billion from its earlier view for $23.8 billion to $24.5 billion. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Lincluden Management Ltd. increased its position in Teva Pharmaceutical Industries by 7.8% in the fourth quarter.

One interesting bit of information in the reports is that Teva identified certain unspecified trends in the USA generic market that led the company to reassess its business generic unit's policy in the US. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. The return on equity ratio or ROE stands at 4 percent while most common profitability ratio return on investment (ROI) was 3.6 percent. Sales, however, increased 13% year over year, mainly due to the inclusion of Actavis revenues. Company shares were recently noted -17.80% off of the 50-day high and -0.44% away from the 50-day low. If you are reading this story on another website, it was illegally stolen and reposted in violation of U.S. and global copyright legislation.

Several other research analysts have also issued reports on TEVA.

Teva Pharmaceutical Industries Limited (TEVA) has been given an average price target of $36.91 from analysts, according to data collected by Finviz. Finally, Sterling Investment Advisors Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter.

Teva Pharmaceutical Industries Limited (TEVA) has a market capitalization of 24.11 Billion which suggests the company is a huge company further suggesting that the shares of Teva Pharmaceutical Industries Limited (TEVA) are stable and safe compared to the lower market capitalization companies. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Buy" rating by Guggenheim on Friday, December 4.

Among 26 analysts covering Teva Pharma (NYSE:TEVA), 10 have Buy rating, 0 Sell and 16 Hold. Also, the current price highlights a discount of 30.85% to analysts' high consensus price target.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. In specialty medicines, Teva has treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system. The Firm operates through two divisions: Generic medicines and Specialty medicines.

Related news